24618303
OBJECTIVE	This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis .
METHODS	A single-centre , prospective , randomised , double-blind , placebo-controlled study was carried out .
METHODS	Assessments were made using the Rhinoconjunctivitis Quality of Life Questionnaire and symptom scales .
RESULTS	A total of 128 patients ( aged 13-51 years ) were randomly assigned to one of two groups .
RESULTS	In the montelukast group , patients were treated with montelukast tablets and fluticasone propionate nasal spray ( n = 64 ) .
RESULTS	In the placebo group , treatment comprised a placebo and fluticasone propionate .
RESULTS	The results showed significant improvements in symptom scores and quality of life scores for both groups after one month and two months of treatment , compared with baseline values ; these improvements were significantly greater for the montelukast group compared with the placebo group .
RESULTS	The mean number of loratadine tablets taken by each patient during the study period was only 0.73 for the montelukast group compared with 9 for the placebo group .
CONCLUSIONS	The combination of montelukast tablets and fluticasone propionate nasal spray improved symptom control and overall quality of life for moderate to severe allergic rhinitis patients .

